Yesterday's news was all about Medtronic's (NYSE:MDT) proposed transaction with Covidien (UNKNOWN:COV.DL). But let's take a brief look at whether this tie-up implicates Medtronic as a potentially attractive investment. Of course, there were already reasons to like Medtronic -- it has significant exposure to international and emerging markets, and don't forget that the slow-growing med-tech behemoth is a dividend aristocrat (with at least 25 consecutive years of dividend increases to earn that designation). So, do the shares look attractive?
In the video below, health care analysts Michael Douglass and David Williamson give their thoughts on the investing case for Medtronic.